Actuate Therapeutics, Inc. (ACTU)
0.3202
-0.01
(-2.08%)
USD |
NASDAQ |
Nov 06, 10:23
Actuate Therapeutics Enterprise Value : 3.832M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 3.832M |
| November 04, 2026 | 4.862M |
| November 03, 2026 | 4.384M |
| November 02, 2026 | 4.192M |
| October 30, 2026 | 4.026M |
| October 29, 2026 | 4.888M |
| October 28, 2026 | 5.184M |
| October 27, 2026 | 5.573M |
| October 26, 2026 | 8.656M |
| October 23, 2026 | 7.390M |
| October 22, 2026 | 8.375M |
| October 21, 2026 | 9.480M |
| October 20, 2026 | 10.77M |
| October 19, 2026 | 10.36M |
| October 16, 2026 | 10.51M |
| October 15, 2026 | 7.984M |
| October 14, 2026 | 6.406M |
| October 13, 2026 | 7.177M |
| October 12, 2026 | 11.44M |
| October 09, 2026 | 10.63M |
| October 08, 2026 | 12.28M |
| October 07, 2026 | 13.37M |
| October 06, 2026 | 15.47M |
| October 05, 2026 | 16.99M |
| October 02, 2026 | 15.65M |
| Date | Value |
|---|---|
| October 01, 2026 | 17.33M |
| September 30, 2026 | 14.70M |
| September 29, 2026 | 12.45M |
| September 28, 2026 | 13.66M |
| September 25, 2026 | 12.31M |
| September 24, 2026 | 10.87M |
| September 23, 2026 | 13.55M |
| September 22, 2026 | 15.37M |
| September 21, 2026 | 17.77M |
| September 18, 2026 | 19.54M |
| September 17, 2026 | 19.88M |
| September 16, 2026 | 19.93M |
| September 15, 2026 | 19.60M |
| September 14, 2026 | 20.71M |
| September 11, 2026 | 21.67M |
| September 10, 2026 | 23.59M |
| September 09, 2026 | 26.24M |
| September 08, 2026 | 28.88M |
| September 04, 2026 | 31.52M |
| September 03, 2026 | 28.88M |
| September 02, 2026 | 27.20M |
| September 01, 2026 | 32.96M |
| August 31, 2026 | 32.48M |
| August 28, 2026 | 35.72M |
| August 27, 2026 | 36.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 579.64B |
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.867M |
| Total Expenses (Quarterly) | 4.867M |
| EPS Diluted (Quarterly) | -0.2039 |
| Earnings Yield | -278.4% |
| Normalized Earnings Yield | -278.42 |